非小细胞肺癌（NSCLC）是肺癌的主要病理类型。在这项研究中，多组学分析显示 NSCLC 中假尿苷合酶 1 (PUS1) 显着增加，并且 PUS1 的高表达与较短的 OS（总生存期）、PFS（无进展生存期）和 PPS（进展后生存期）相关）非小细胞肺癌（NSCLC）患者。临床亚组分析显示PUS1可能参与NSCLC的发生、发展。此外，TIMER、ESTIMATE和IPS分析提示PUS1表达与免疫细胞浸润相关，且PUS1表达与DC细胞浸润呈显着负相关。 GESA分析还表明，PUS1可能参与DNA_REPAIR、E2F_TARGETS、MYC_TARGETS_V2、G2M_CHECKPOINT和MYC_TARGETS_V1通路，并通过MCM5或XPO1触发NSCLC恶性肿瘤。此外，PUS1可能是NSCLC治疗的潜在靶点。

Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer. In this study, multi-omics analysis revealed a significant increase of pseudouridine synthase 1 (PUS1) in NSCLC and the high expression of PUS1 was associated with shorter OS (Overall Survival), PFS (Progression Free Survival), and PPS (Post Progression Survival) of NSCLC patients. Clinical subgroup analysis showed that PUS1 may be involved in the occurrence and development of NSCLC. Besides, TIMER, ESTIMATE, and IPS analysis suggested that PUS1 expression was associated with immune cell infiltration, and the expression of PUS1 was significantly negatively correlated with DC cell infiltration. GESA analysis also indicated PUS1 may involve in DNA_REPAIR, E2F_TARGETS, MYC_TARGETS_V2, G2M_CHECKPOINT and MYC_TARGETS_V1 pathways and triggered NSCLC malignancy through MCM5 or XPO1. Furthermore, PUS1 may be a potential target for NSCLC therapy.